Telaprevir for previously treated chronic HCV infection.

@article{McHutchison2010TelaprevirFP,
  title={Telaprevir for previously treated chronic HCV infection.},
  author={John McHutchison and Michael P. Manns and Andrew J. Muir and Norah A Terrault and Ira M Jacobson and Nezam H. Afdhal and Elizabeth Jenny Heathcote and Stefan Zeuzem and Hendrik W Reesink and Jyotsna Garg and Mohammad Bsharat and Shelley Joseph George and Robert S. Kauffman and Nathalie Adda and Adrian M Di Bisceglie},
  journal={The New England journal of medicine},
  year={2010},
  volume={362 14},
  pages={
          1292-303
        }
}
BACKGROUND Patients with genotype 1 hepatitis C virus (HCV) who do not have a sustained response to therapy with peginterferon alfa and ribavirin have a low likelihood of success with retreatment. METHODS We randomly assigned patients with HCV genotype 1 who had not had a sustained virologic response after peginterferon alfa-ribavirin therapy to one of four treatment groups: 115 patients to the T12PR24 group, receiving telaprevir (1125-mg loading dose, then 750 mg every 8 hours) for 12 weeks… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 390 CITATIONS, ESTIMATED 44% COVERAGE

Emerging Therapies for Hepatitis C

VIEW 5 EXCERPTS
CITES RESULTS
HIGHLY INFLUENCED

When should a hepatitis C-positive ESRD patient receive a renal transplant?

  • Seminars in dialysis
  • 2011
VIEW 11 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Treatment of hepatitis C virus infection in the future

  • Clinical and translational medicine
  • 2013
VIEW 6 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

Efficacy and safety of telaprevir in patients with genotype 1 hepatitis C infection.

  • Therapeutic advances in gastroenterology
  • 2012
VIEW 9 EXCERPTS
CITES RESULTS, BACKGROUND & METHODS
HIGHLY INFLUENCED

Telaprevir: an oral protease inhibitor for hepatitis C virus infection.

  • American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
  • 2012
VIEW 8 EXCERPTS
CITES METHODS, RESULTS & BACKGROUND
HIGHLY INFLUENCED

Current therapies for chronic hepatitis C.

  • Pharmacotherapy
  • 2011
VIEW 14 EXCERPTS
CITES METHODS & BACKGROUND
HIGHLY INFLUENCED

Management of untreated and nonresponder patients with chronic hepatitis C.

  • Seminars in liver disease
  • 2010
VIEW 5 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

2008
2018

CITATION STATISTICS

  • 22 Highly Influenced Citations

  • Averaged 6 Citations per year from 2017 through 2019

References

Publications referenced by this paper.
SHOWING 1-10 OF 12 REFERENCES

Re - treatment of patients with chronic hepatitis who do not respond to peginter - feron - 2 b

C Lin, AD Kwong, RB Perni
  • Ann Intern Med
  • 2009

The effects of interferon alpha - 2 b in combination with ribavirin on health related quality of life and work productivity

C Cammà, D DiBona, F Schepis
  • Hepatology
  • 2001

Similar Papers

Loading similar papers…